Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00410696
Status:
COMPLETED
Last Update Posted:
2013-07-01
First Post:
2006-12-12
Brief Title:
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
Sponsor:
Armando Santoro MD
Organization:
Istituto Clinico Humanitas
Study Overview
Official Title:
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy With Peripheral Autologous Stem Cell Reinfusion in Patients With Hematological Neoplasms and Solid Tumors Phase II Randomised Trial
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to evaluate the efficacy and the safety of pegfilgrastim versus filgrastim administered after high-dose chemotherapy and peripheral stem cell reinfusion
Detailed Description:
Secondary objective is to evaluate the immunological reconstitution after pegfilgrastim and filgrastim
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2006-001409-27 | None | None | None |